Detalhe da pesquisa
1.
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.
BMC Cancer
; 23(1): 265, 2023 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36949413
2.
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Lancet
; 395(10241): 1907-1918, 2020 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32473681
3.
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
JAMA Oncol
; 9(1): 128-134, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36326731
4.
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.
JAMA Oncol
; 9(10): 1390-1400, 2023 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589970
5.
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study.
Elife
; 122023 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37846664
6.
Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
medRxiv
; 2023 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37205429
7.
Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.
JAMA Netw Open
; 5(1): e2142046, 2022 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34982158
8.
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.
JAMA Oncol
; 2021 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34137799
9.
Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603).
JNCI Cancer Spectr
; 4(1): pkz088, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32337497
10.
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis.
Clin Lung Cancer
; 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38744613
11.
Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Cancer Med
; 7(11): 5382-5393, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30123970